Having trouble accessing articles? Reset your cache.

Perampanel: Phase III data

In the double-blind, dose-escalation, international Phase III Study 306 trial in 706 patients, 4 and 8 mg doses of perampanel as an adjunctive therapy met the primary endpoint of significantly reducing

Read the full 310 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE